Age years; sex | Follow-up years | Lung disease | Personal and familial history | Biomarkers | Treatments | ||||||
Severe asthma | Recurrent hypoxaemia; FEV1/FVC % | Chest CT | Other eosinophilic organ involvement | Familial history | BEC ×109 cells·L−1; FENO ppb; % eosinophil BAL; total IgE IU·mL−1; specific IgE IU·mL−1 | ANCA and CRP | OCS years; bolus of CS; impact on growth; normalised LF | Biologics: follow-up years – TC, PC, NC | Benralizumab follow-up months; possibility of OCS discontinuation; BEC×109 cells·L−1; FENO ppb | ||
8; girl | 4 | Multiple hospitalisations /multiple intensive care | Yes; 84 | PIN; SA | Chronic rhinosinusitis; GOR | Atopic dermatitis | 1.810; 247; 0; 342; HDM 15.6 | Negative ANCA and CRP | 1; no; yes | Omalizumab: 1 – NC | 5 –TC; yes; 0.58; NA |
7; boy | 8 | Multiple hospitalisations | Yes; 69 | PIN; HI | Nasal polyposis; VKC; epilepsy | Food allergies | 1.550; 150; NA; 66; positive SAE | Negative ANCA and CRP | 5; yes; yes | Omalizumab: 1 – TC and relapse; mepolizumab: 0.5 – TC and relapse | 10 – TC; yes; 0; NA |
5; boy | 4 | Multiple hospitalisations | Yes; 71 | PIN; BWT; HI; IST | Nasal polyposis | Allergic rhinitis | 5.000; 35; 5; 92; positive SAE | Negative ANCA and CRP | 3; multiple; yes; yes | Omalizumab: 1 – PC; Mepolizumab: 1.5 – PC and relapse | 12 – PC; yes; 0; NA |
6; boy | 8 | Multiple hospitalisations /multiple intensive care | Yes; 71 | PIN; BWT; HI; DMA | Chronic rhinosinusitis Chronic urticaria | None | 1.700; 120; 45; NA; negative | Negative ANCA and CRP | 3; multiples; yes; yes | Omalizumab: 4 – TC and relapse; mepolizumab: 0.5 – PC and relapse | 6 – PC; no; 0; 111 |
9; boy | 4 | Multiple hospitalisations | No; 68 | PIN; BWT; HI | Chronic rhinosinusitis Atopic dermatitis | Asthma | 40.400; 49; 38; 1447; positive SAE | Negative ANCA and CRP | 1; multiples; no; yes | Omalizumab: 0.5 – NC; cyclosporine: 0.5 – PC; mepolizumab: 0.5 – NC | 10 – TC; yes; 0; NA |
5; girl | 10 | Multiple hospitalisations /multiple intensive care | Yes; 57 | PIN; BWT; HI; IST; DMA | Nasal polyposis | Type 1 diabetes | 2.100; 100; 7; 226; positive SAE | Negative ANCA and CRP | 4; yes; no | Omalizumab: 4 – PC and relapse; mepolizumab: 0.5 – NC | 6 – TC; yes; normalised LF 0; NA |
FEV1: forced expiratory volume in 1; FVC: forced vital capacity; CT: computed tomography; FENO: exhaled nitric oxide fraction; CS: corticosteroid; PIN: pulmonary infiltrates and nodules; SA: segmental atelectasis; BWT: bronchial wall thickening; HI: hyperinflation; IST: interlobular septal thickening; DMA: diffuse mosaic attenuation; GOR: gastro-oesophageal reflux; VKC: vernal kerato-conjunctivitis; peak BEC: blood eosinophil count; BAL: bronchoalveolar lavage; peak total IgE (measured by ImmunoCAP): specific IgE towards common specific inhaled mould, food allergens and staphylococcal toxins (ImmunoCAP Phadiatop Infant; Uppsala, Sweden); HDM: house dust mites-specific IgE (≥0.35 kU·L−1); SAE: Staphylococcus aureus enterotoxins-specific IgE (≥0.35 kU·L−1); ANCA: anti-neutrophil cytoplasmic antibody; CRP: C-reactive protein; OCS: oral corticosteroid; LF: lung function; TC: total control; PC: partial control, as defined by the Global Initiative for Asthma; NC: no control; NA: not available.